Loading...
XKRX
009290
Market cap256mUSD
Oct 08, Last price  
6,920.00KRW
1D
0.29%
1Q
10.02%
Jan 2017
-18.78%
Name

Kwangdong Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XKRX:009290 chart
P/E
16.39
P/S
0.21
EPS
422.23
Div yield, %
1.45%
Shrs. gr., 5y
5.28%
Rev. gr., 5y
5.94%
Revenues
1.66t
+1.15%
250,523,205,000276,172,800,000276,585,200,000289,434,907,000313,986,322,520332,641,298,450468,384,619,950522,274,344,500955,453,631,8401,056,428,809,4901,141,565,921,0101,180,219,946,7101,238,254,696,0001,243,769,596,0001,338,181,554,0001,431,545,255,0001,514,454,148,0001,640,718,849,0001,659,512,458,000
Net income
20.97b
-48.20%
24,162,480,00021,406,809,00023,185,826,00025,213,710,00029,923,095,00027,823,695,65022,037,369,44035,043,972,22035,015,307,52028,062,800,77023,196,129,92022,345,018,97023,058,316,00045,369,773,00024,019,071,00024,173,931,00036,965,562,00040,480,913,00020,968,451,000
CFO
82.34b
P
36,255,245,00016,305,760,00026,275,191,00030,709,004,00027,678,908,97023,738,268,99034,394,125,26032,750,105,08041,143,925,45028,799,301,06023,464,845,77053,096,472,40029,285,288,00022,828,703,00054,939,860,00062,822,034,000-11,730,405,000-12,153,334,00082,341,354,000
Dividend
Mar 31, 2026100 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in Seoul, South Korea, in 1963, Kwang Dong Pharmaceutical Co., Ltd. functions as a diversified healthcare enterprise. The company is actively involved in the development and distribution of an extensive range of pharmaceutical products. This portfolio includes various over-the-counter (OTC) remedies addressing common ailments such as coughs and colds, eye care, liver conditions, mineral deficiencies, vitamin supplementation, circulatory health, and general wellness tonics. Complementing these are its prescription-only (ETC) medicines, which encompass treatments for a broad spectrum of medical needs, including diabetes, cardiovascular disorders, metabolic imbalances, digestive issues, immune system modulation, obesity, genitourinary and anal conditions, neurological and psychiatric disorders, pain and inflammation, infections, and anti-cancer therapies. Beyond pharmaceuticals, Kwang Dong offers health supplements and a diverse selection of beverages, ranging from general consumer drinks to functional and traditional health-focused options. The company also extends its operations to include the management of hospitals and facilitates widespread product distribution through various retail and wholesale channels, including discount stores, television home shopping, and online e-commerce platforms. Furthermore, Kwang Dong Pharmaceutical acts as a comprehensive MRO (Maintenance, Repair, and Operations) service provider, specializing in the procurement of raw materials, intermediate goods, and industrial consumables, with services extending to construction and international sourcing.

Key people

Seong Won Choi
Co-Chief Executive Officer, Director · since 2025
Yeong Deok Gi
Vice President
Hyeon Sik Kim
Vice President, Director · since 2008
Managing Director
Yin Jae Lee
Managing Director · since 2012
Chun Sik Choi
Internal Auditor
Bo Hyeong Lee
Assistant Managing Director
Ju Hyeong Park
Internal Auditor · since 2017
Cheol Su Park
Assistant Managing Director · since 2009
Do Hui Won
Internal Auditor
Gwa Gyun Mo
Vice President, Director · since 2013
Sang Yeong Park
Co-Chief Executive Officer, Director · since 2025
Gyeong Muk Yim
Non-Executive Independent Director · since 2013
IPO date
Nov 17, 1989
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT